New Novartis data in relapsing MS reinforce benefits of Kesimpta…
WEB3 days ago · Nearly 90% of first-line Kesimpta patients had no disability progression independent of relapse activity (PIRA) for up to six years in an analysis of open-label ALITHIOS extension study1 More than 80% of patients receiving first-line Kesimpta were progression-free for up to six years, reinforcing the value of introducing Kesimpta early1 Patients switching to Kesimpta from IV anti-CD20 therapy ...
Novartis publishes new five-year efficacy data on Kesimpta® …
WEBJun 30, 2023 · Kesimpta (ofatumumab) is a treatment for relapsing multiple sclerosis (RMS) that showed sustained efficacy, low relapse rates and high NEDA-3 rates in a long-term study. The data were presented at the European Academy of Neurology Annual Meeting in July 2023.
FDA approves Novartis Kesimpta® (ofatumumab), the first and …
WEBAug 20, 2020 · Kesimpta is a self-administered, targeted B-cell therapy for relapsing forms of multiple sclerosis (RMS), shown to reduce relapses, disability progression and brain lesions. It is the first and only B-cell therapy that can be injected at home once monthly with a Sensoready pen.
AAN 2023: MS disability not worse for most on Kesimpta 5 years
WEBApr 28, 2023 · Kesimpta, a B-cell depleting therapy, reduced disability worsening and brain atrophy in people with relapsing MS over five years, according to new data presented at AAN 2023. The therapy...
AAN 2024: Long-term data support early Kesimpta start in …
WEBApr 19, 2024 · Long-term data from ASCLEPIOS and ALITHIOS studies show that Kesimpta (ofatumumab) reduces relapses, lesions, and disability progression in recently diagnosed MS patients. Starting Kesimpta...
Novartis Kesimpta® six-year efficacy data show substantial …
WEBApr 17, 2024 · Novartis announced six-year data from ALITHIOS study showing sustained benefits of Kesimpta® (ofatumumab) for people with relapsing multiple sclerosis (RMS). Kesimpta® reduced relapses, MRI...
Novartis presents new five-year data on disability outcomes and …
WEBApr 20, 2023 · Kesimpta is a targeted, precisely dosed and delivered B-cell therapy that provides the flexibility of self-administration for adults with relapsing forms of multiple sclerosis (RMS). It is an...
FDA approves Novartis Kesimpta® (ofatumumab), the first and …
WEBBasel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta ® (ofatumumab, formerly OMB157) as an injection for subcutaneous use for the...
Kesimpta reduces relapses, brain lesions for up to 5 years: Study
WEBJul 6, 2023 · Up to five years of treatment with Kesimpta (ofatumumab) continues to keep the number of relapses and brain lesions low in people with relapsing forms of multiple sclerosis (MS), with most...
Head-to-Head Comparison of Kesimpta vs Ocrevus Treatment in …
WEBMay 29, 2024 · A real-world study compared Kesimpta and Ocrevus treatment in patients with MS using Optum Clinformatics claims data. The study found similar persistence and adherence of Kesimpta and Ocrevus at 18 and 24 months post index.
Skip to content